Page last updated: 2024-11-12

macelignan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

macelignan: an NSAID with antioxidant, free radical scavenging, and neuroprotective activities; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10404245
CHEMBL ID254071
CHEBI ID94153
SCHEMBL ID1783132
MeSH IDM0486938

Synonyms (41)

Synonym
(+)-anwulignan
smr000445701
MLS000728494 ,
CHEMBL254071
austrobailignan 6
107534-93-0
(8r,8's)-7-(3,4-methylenedioxyphenyl)-7'-(4-hydroxy-3-methoxyphenyl)-8,8'-dimethylbutane
unii-8pp3614z43
8pp3614z43 ,
phenol, 4-((2s,3r)-4-(1,3-benzodioxol-5-yl)-2,3-dimethylbutyl)-2-methoxy-
anwulignan
macelignan
HMS2219A18 ,
S9146
anwuligan
macelignan [inci]
CS-3657
(2r,3s)-1-(3,4-methylenedioxyphenyl)-2,3-dimethyl-4-(4-hydroxy-3-methoxyphenyl)-butane
SCHEMBL1783132
4-((2s,3r)-4-(benzo[d][1,3]dioxol-5-yl)-2,3-dimethylbutyl)-2-methoxyphenol
4-[(2s,3r)-4-(1,3-benzodioxol-5-yl)-2,3-dimethylbutyl]-2-methoxyphenol
cid_10404245
4-[(2s,3r)-4-(1,3-benzodioxol-5-yl)-2,3-dimethyl-butyl]-2-methoxy-phenol
bdbm90735
AC-33989
Q-100926
HY-N0064
DTXSID00148077
mfcd09953803
CHEBI:94153
macelignan, >=98% (hplc)
calophyn
DB14129
(+)-anwulignan;anwuligan
Q6723225
HMS3886J18
CCG-267793
AS-56147
AKOS037645016
phenol,4-[(2s,3r)-4-(1,3-benzodioxol-5-yl)-2,3-dimethylbutyl]-2-methoxy-
A895427

Research Excerpts

Overview

Macelignan is a lignin isolated from the seeds of Myristica fragrans. It possesses many types of health benefits such as antiinflammation.

ExcerptReferenceRelevance
"Macelignan is a lignin isolated from the seeds of Myristica fragrans."( Macelignan protects against renal ischemia-reperfusion injury via inhibition of inflammation and apoptosis of renal epithelial cells.
Li, J; Liu, J; Long, J; Qian, K; Tan, S, 2020
)
2.72
"Macelignan is a natural phenolic compound that possesses many types of health benefits such as antiinflammation. "( Glucuronidation of macelignan by human liver microsomes and expressed UGT enzymes: identification of UGT1A1 and 2B7 as the main contributing enzymes.
Liu, H; Ma, Z; Wu, B; Wu, Z, 2014
)
2.17

Effects

ExcerptReferenceRelevance
"Macelignan has been shown to possess a spectrum of pharmacological activities, including anti-bacterial, anti-inflammatory, anti-cancer, anti-diabetes, and hepatoprotective activities; recently, it has also been shown to have neuroprotective activities."( Multiple biological properties of macelignan and its pharmacological implications.
Chung, C; Han, JS; Hwang, JK; Jeon, WK; Kim, HY; Paul, S, 2013
)
1.39

Treatment

Treatment with macelignan for 4 d significantly prevented the increased serum enzymatic activities of alanine and aspartate aminotransferase in a dose-dependent manner.

ExcerptReferenceRelevance
"Treatment with macelignan attenuated eosinophilic airway inflammation and airway hyper-responsiveness. "( Macelignan attenuated allergic lung inflammation and airway hyper-responsiveness in murine experimental asthma.
Chung, HC; Hwang, JK; Kim, DU; Lee, SH; Shin, K, 2013
)
2.19
"Pretreatment with macelignan for 4 d significantly prevented the increased serum enzymatic activities of alanine and aspartate aminotransferase in a dose-dependent manner."( Protective Effects of macelignan on cisplatin-induced hepatotoxicity is associated with JNK activation.
Han, KL; Hwang, JK; Kim, JH; Rukayadi, Y; Sohn, JH, 2008
)
0.98

Bioavailability

ExcerptReferenceRelevance
"This study investigated the effect of macelignan on the P-glycoprotein-mediated drug efflux as well as CYP3A4-mediated drug metabolism and subsequently its in vivo implication on the bioavailability of paclitaxel."( Effect of maceligan on the systemic exposure of paclitaxel: in vitro and in vivo evaluation.
Ha, I; Han, HK; Kang, KW; Lee, BJ; Qiang, F; Woo, ER, 2010
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
lignanAny phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e".
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency24.84460.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency1.00000.180013.557439.8107AID1460
Smad3Homo sapiens (human)Potency22.38720.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency22.38720.707912.194339.8107AID720542
serine-protein kinase ATM isoform aHomo sapiens (human)Potency35.48130.707925.111941.2351AID485349
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency22.21630.036619.637650.1187AID2100
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency79.43280.425612.059128.1838AID504891
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
VprHuman immunodeficiency virus 1Potency56.23411.584919.626463.0957AID651644
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency31.62283.981146.7448112.2020AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
corticotropin-releasing hormone receptor 2Homo sapiens (human)IC50 (µMol)47.10000.36807.095518.0000AID602180
corticotropin releasing factor-binding proteinHomo sapiens (human)IC50 (µMol)47.10000.36807.095518.0000AID602180
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
corticotropin-releasing hormone receptor 2Homo sapiens (human)EC50 (µMol)53.00001.120011.561736.8000AID602473
corticotropin releasing factor-binding proteinHomo sapiens (human)EC50 (µMol)53.00001.120011.561736.8000AID602473
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID313420Antioxidant activity against LDL-oxidation by TBARS assay2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Low-density lipoprotein (LDL)-antioxidant lignans from Myristica fragrans seeds.
AID1155648Neuroprotective activity against amyloid beta (25 to 35)-induced cell death in human SH-SY5Y cells assessed as cell viability at 0.4 uM after 24 hrs by MTT assay relative to control2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Lignans from the fruit of Schisandra glaucescens with antioxidant and neuroprotective properties.
AID323984Proliferative effect in human MCF7 BUS cells assessed as ratio of increase in cell number in drug treated to control2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Structure and estrogenic activity of new lignans from Iryanthera lancifolia.
AID1155644Antioxidant activity assessed as 300 uM DPPH free radical scavenging activity under dark condition after 30 mins by microplate reader analysis2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Lignans from the fruit of Schisandra glaucescens with antioxidant and neuroprotective properties.
AID323986Proliferative potency in human MCF7 BUS cells assessed as induction of maximal cell proliferation relative to 17-beta estradiol2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Structure and estrogenic activity of new lignans from Iryanthera lancifolia.
AID1155650Neuroprotective activity against amyloid beta (25 to 35)-induced cell death in human SH-SY5Y cells assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Lignans from the fruit of Schisandra glaucescens with antioxidant and neuroprotective properties.
AID323985Proliferative effect in human MCF7 BUS cells assessed as increase in cell number relative to 17-beta estradiol2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Structure and estrogenic activity of new lignans from Iryanthera lancifolia.
AID1155649Neuroprotective activity against amyloid beta (25 to 35)-induced cell death in human SH-SY5Y cells assessed as cell viability at 2 uM after 24 hrs by MTT assay relative to control2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Lignans from the fruit of Schisandra glaucescens with antioxidant and neuroprotective properties.
AID313419Antioxidant activity assessed as inhibition of LDL-oxidation at 20 uM by TBARS assay2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Low-density lipoprotein (LDL)-antioxidant lignans from Myristica fragrans seeds.
AID1155645Antioxidant activity assessed as reduction of TPTZ-Fe3+ to TPTZ-Fe2+ after 5 mins by FRAP assay2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Lignans from the fruit of Schisandra glaucescens with antioxidant and neuroprotective properties.
AID1155647Neuroprotective activity against amyloid beta (25 to 35)-induced cell death in human SH-SY5Y cells assessed as cell viability at 0.08 uM after 24 hrs by MTT assay relative to control2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Lignans from the fruit of Schisandra glaucescens with antioxidant and neuroprotective properties.
AID1155643Antioxidant activity assessed as 150 uM DPPH free radical scavenging activity under dark condition after 30 mins by microplate reader analysis2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Lignans from the fruit of Schisandra glaucescens with antioxidant and neuroprotective properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (37.84)29.6817
2010's17 (45.95)24.3611
2020's6 (16.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.87 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index37.30 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (24.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (97.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]